Treatment of agitation in Alzheimer disease, text messaging for CV risk modification, a newly approved PCSK9 inhibitor for dyslipidemia, and more.

JAMA Editor’s Summary

Treatment of agitation in Alzheimer disease, text messaging for CV risk modification, a newly approved PCSK9 inhibitor for dyslipidemia, and more.

Editor's Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the

September 22, 2015

Listen on your favorite player Take me to this show’s page

Newer →

Minimally invasive surgery for rectal cancer and diverticulitis, rehabilitation after immobilization for ankle fracture, long-term outcomes after carpal tunnel release, and more.

← Older

Time Spent Outdoors and Development of Myopia in Children, Sex Differences in Academic Rank in US Medical Schools, Mortality After Hip Fracture vs Elective Hip Replacement, and more

Facebook Twitter Buffer LinkedIn WhatsApp

Treatment of agitation in Alzheimer disease, text messaging for CV risk modification, a newly approved PCSK9 inhibitor for dyslipidemia, and more.

Editor’s Audio Summary by Howard Bauchner, MD, Editor in Chief of JAMA, the Journal of the American Medical Association, for the September 22/29, 2015 issue

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

00:00

00:00